المؤلفون: Rodrigueza WV; ProNAi Therapeutics, Inc., Plymouth, MI, USA, wrodrigueza@pronai.com., Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2014 Jul; Vol. 74 (1), pp. 151-66. Date of Electronic Publication: 2014 May 16.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , DNA, Antisense/*therapeutic use , DNA, Single-Stranded/*therapeutic use , Gene Silencing/*drug effects , Neoplasms/*drug therapy , Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors, 5' Flanking Region/drug effects ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/metabolism ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cell Line, Tumor ; Cell Survival/drug effects ; DNA, Antisense/administration & dosage ; DNA, Antisense/pharmacokinetics ; DNA, Antisense/pharmacology ; DNA, Single-Stranded/administration & dosage ; DNA, Single-Stranded/pharmacokinetics ; DNA, Single-Stranded/pharmacology ; Drug Compounding ; Drug Stability ; Female ; Liposomes ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mice, SCID ; Neoplasms/blood ; Oligodeoxyribonucleotides/chemistry ; Oligodeoxyribonucleotides/pharmacokinetics ; Oligodeoxyribonucleotides/pharmacology ; Oligodeoxyribonucleotides/therapeutic use ; Pharmaceutical Vehicles ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Random Allocation ; Xenograft Model Antitumor Assays